Johnson & Johnson(JNJ) - Stock detail

Johnson & Johnson

US
JNJ
Johnson & Johnson(Listing date: 09/25/1944)

Johnson & Johnson was incorporated in New Jersey in 1887. Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacturing and sale of various products in the healthcare field. Johnson & Johnson is a holding company, with its operating companies located in nearly all countries around the world. The company's primary focus is on products related to human health and well-being. The company is divided into two business segments: Innovative Medicine and MedTech.

AI Debate JudgeSell
Generated at:2026-06-04 05:44:38
Data source: real-time quotes, news and fundamental analysis, analysis date: 2026-06-03
  • The bearish arguments are more persuasive because they are based on what the market *is doing right now*, not what the company *should be* worth in theory.
  • Furthermore, the technical evidence of a confirmed downtrend, a death cross, and severe selling pressure (MFI of 0.37) is overwhelming and current.
  • Moreover, the market structure creates a clear near-term risk: an estimated 76% of holders are underwater, forming a wall of 'overhead supply' that caps rallies around the $228 average cost.
  • Therefore, the bullish case, while sound for long-term income, fails to address the immediate and powerful bearish price action and risk of further short-term downside.
Bear Case
  • Technical picture shows confirmed downtrend with death cross and price below all key moving averages.
  • Severe, sustained selling pressure evidenced by catastrophic Money Flow Index (MFI) of 0.37.
  • High-volume distribution creates a clear resistance ceiling from 'overhead supply' with 76% of holders underwater.
  • Bullish arguments ignore the immediate price action and risk of a classic value trap.
Bull Case
  • Relies on narrative and long-term qualities like 'Dividend King' status.
  • Argues the dip improves yield and presents a buying opportunity based on oversold conditions.
  • Highlights normalized valuation metrics and a fundamentally sound pipeline for long-term investors.
  • Points to company diversification and income focus as reasons for patience.

Price Targets

Analysis Summary

📊 Target Price Analysis:

Based on synthesizing the reports:

  • Fundamentals: The fundamentals report suggests a normalized valuation range of $288-$302, but this is a long-term, idealized target. More immediately, it notes a near-term trading range of $215-$245.
  • Technical: The technical analysis identifies immediate support at $219-$221 and strong resistance at $233-$235. With the current bearish alignment, a test of support is the higher-probability path.
  • News/Sentiment: The news analysis suggests a neutral-to-slightly negative short-term impact and a consolidation range, aligning with the technical view of a lack of immediate bullish catalysts.

Specific Price Targets:

  • 1-Month Target (Conservative/Bearish Scenario): $215 - $218. This anticipates a successful test and possible brief break of the $219 support, targeting the next psychological and technical zone lower.
  • 3-Month Target (Baseline Scenario): $210 - $225. This assumes the downtrend continues or consolidates at a lower range. Resistance at the moving average cluster (now around $227-$230) caps upside. The lower end reflects a potential overshoot if market sentiment sours further.
  • 6-Month Target (Optimistic/Reversal Scenario): $235 - $245. This scenario only becomes valid if the stock can consolidate, build a base, and stage a volume-backed reversal to reclaim its key moving averages. The $235-245 zone represents the 60-day MA and prior resistance. This is not the current higher-probability path.

Bottom Line: The weight of evidence points to continued weakness or sideways consolidation with a downside bias. The prudent action is to defend capital by reducing exposure on rallies and respecting the clear downtrend. We will look for a significant change in market structure and momentum before re-evaluating the long-term bullish fundamental thesis.

Action Strategy

Strategy Summary

Strategic Actions:

  1. For existing holders: Implement a reduction strategy. Use any oversold bounce towards the $228-$230 resistance zone (the cluster of the 10-day MA and the estimated average cost) to sell a portion of the position. This respects the overhead supply risk.
  2. Set a definitive stop-loss: For any remaining position, place a hard stop-loss order just below the recent key support at $219 (the lower Bollinger Band). A break below this level confirms a new leg down in the trend.
  3. For new capital: Avoid initiating any long positions. The condition for reconsideration would be a strong, high-volume close back above the 20-day EMA (currently ~$227.66) and preferably the 60-day MA (~$233). Until then, the bias is to the downside.
AI Bull vs AI Bear
Round-by-round arguments

Round 1 - Bear case

  • The analyst argues JNJ's "Dividend King" status is backward-looking and not a current support, as the stock price has fallen from $247 to $223, breaking through dividend-yield support. Technically, the chart shows a bear trend with a death cross, negative MACD, and severe selling pressure (MFI at 0.37). Overhead supply is a major risk, with an estimated 76% of holders at a loss, likely selling into any rally. Fundamentally, valuations are deemed unappealing, using an unsustainable 50.24% net margin, leading to a high P/S of 24.55. Growth is stagnant with no near-term catalysts, while macro risks like high interest rates pressure its valuation.

Detail Preview

Let's cut through the dividend daydream and get real about Johnson & Johnson. I’ve reviewed the data—technical, fundamental, and news—and the bullish case is resting on a crumbling pillar of past glory while ignoring a heap of present risks. Here’s why you should be extremely cautious, if not outright bearish, on JNJ right now. Refuting the Bullish "Dividend King" & "Safe Haven" Narrative My bullish friend is likely…

Round 2 - Bear case

  • The stock's decline is a confirmed downtrend, not a buying opportunity, evidenced by a death cross and high-volume selling. Technically, severe selling pressure is shown by a Money Flow Index of 0.37, and a large concentration of underwater holders creates overhead resistance, not support. Valuation is not compelling, with a forward P/E over 20 for a company focused on dividend stability, not growth. Diversification exposes the firm to multiple segment headwinds, and near-term pipeline catalysts are not transformative.

Detail Preview

Alright, let's get straight to the point. While my bullish counterpart is trying to put a positive spin on a clear deterioration, the evidence overwhelmingly supports a cautious, if not outright bearish, stance on Johnson & Johnson. I'll address their points directly. First, on the so-called "buying opportunity" from the pullback. Calling this a mere pullback is a serious mischaracterization. The stock has fallen fro…

Round 1 - Bull case

  • The bullish analyst argues JNJ's recent price pullback is a buying opportunity, not a structural breakdown. They refute bear points by stating: 1) The dividend king status remains forward-looking, with the pullback improving yield. 2) Technical indicators show short-term oversold conditions, and the large holder concentration near current price forms a support zone. 3) Valuation using normalized margins shows a reasonable P/E, not the unsustainable one based on an anomalous quarter. 4) Growth is durable via its diversified healthcare portfolio, strategic M&A, and pipeline catalysts like JNJ-1900.

Detail Preview

Bullish Analyst Rebuttal & Investment Case for Johnson & Johnson (JNJ) Thank you. While my colleague paints a compelling picture of short-term technical weakness, I believe they are mistaking a healthy consolidation and buying opportunity for a structural breakdown. The bear case focuses intensely on the rear-view mirror—past price action and an anomalous quarterly margin—while dismissing the forward-looking pillars…

Round 2 - Bull case

  • The recent price pullback is a healthy consolidation after a strong surge, not a confirmed downtrend, with oversold technical indicators (RSI, Williams %R) suggesting exhaustion. The high percentage of underwater holders does not translate to major selling pressure for this long-term, dividend-focused stock. Bearish valuation using an anomalous Q1 2025 net margin is misleading
  • normalized P/E ratios are fair for a premium asset. JNJ's durable growth stems from its diversified healthcare segments, a robust pipeline, and a strong dividend yield, making it a compelling wealth-preservation asset.

Detail Preview

Bullish Analyst Rebuttal & Constructive Case for JNJ Thank you for the continued debate. While my bearish colleague focuses on short-term price action and selective metrics, they are missing the forest for the trees. The case for JNJ is not about a speculative, momentum-driven surge; it’s about capital preservation, reliable growth, and compounding income in a volatile market. The recent pullback has made that case s…

Round 1 - Bear case

  • The analyst argues JNJ's "Dividend King" status is backward-looking and not a current support, as the stock price has fallen from $247 to $223, breaking through dividend-yield support. Technically, the chart shows a bear trend with a death cross, negative MACD, and severe selling pressure (MFI at 0.37). Overhead supply is a major risk, with an estimated 76% of holders at a loss, likely selling into any rally. Fundamentally, valuations are deemed unappealing, using an unsustainable 50.24% net margin, leading to a high P/S of 24.55. Growth is stagnant with no near-term catalysts, while macro risks like high interest rates pressure its valuation.

Detail Preview

Let's cut through the dividend daydream and get real about Johnson & Johnson. I’ve reviewed the data—technical, fundamental, and news—and the bullish case is resting on a crumbling pillar of past glory while ignoring a heap of present risks. Here’s why you should be extremely cautious, if not outright bearish, on JNJ right now. Refuting the Bullish "Dividend King" & "Safe Haven" Narrative My bullish friend is likely…

Round 1 - Bull case

  • The bullish analyst argues JNJ's recent price pullback is a buying opportunity, not a structural breakdown. They refute bear points by stating: 1) The dividend king status remains forward-looking, with the pullback improving yield. 2) Technical indicators show short-term oversold conditions, and the large holder concentration near current price forms a support zone. 3) Valuation using normalized margins shows a reasonable P/E, not the unsustainable one based on an anomalous quarter. 4) Growth is durable via its diversified healthcare portfolio, strategic M&A, and pipeline catalysts like JNJ-1900.

Detail Preview

Bullish Analyst Rebuttal & Investment Case for Johnson & Johnson (JNJ) Thank you. While my colleague paints a compelling picture of short-term technical weakness, I believe they are mistaking a healthy consolidation and buying opportunity for a structural breakdown. The bear case focuses intensely on the rear-view mirror—past price action and an anomalous quarterly margin—while dismissing the forward-looking pillars…

Round 2 - Bear case

  • The stock's decline is a confirmed downtrend, not a buying opportunity, evidenced by a death cross and high-volume selling. Technically, severe selling pressure is shown by a Money Flow Index of 0.37, and a large concentration of underwater holders creates overhead resistance, not support. Valuation is not compelling, with a forward P/E over 20 for a company focused on dividend stability, not growth. Diversification exposes the firm to multiple segment headwinds, and near-term pipeline catalysts are not transformative.

Detail Preview

Alright, let's get straight to the point. While my bullish counterpart is trying to put a positive spin on a clear deterioration, the evidence overwhelmingly supports a cautious, if not outright bearish, stance on Johnson & Johnson. I'll address their points directly. First, on the so-called "buying opportunity" from the pullback. Calling this a mere pullback is a serious mischaracterization. The stock has fallen fro…

Round 2 - Bull case

  • The recent price pullback is a healthy consolidation after a strong surge, not a confirmed downtrend, with oversold technical indicators (RSI, Williams %R) suggesting exhaustion. The high percentage of underwater holders does not translate to major selling pressure for this long-term, dividend-focused stock. Bearish valuation using an anomalous Q1 2025 net margin is misleading
  • normalized P/E ratios are fair for a premium asset. JNJ's durable growth stems from its diversified healthcare segments, a robust pipeline, and a strong dividend yield, making it a compelling wealth-preservation asset.

Detail Preview

Bullish Analyst Rebuttal & Constructive Case for JNJ Thank you for the continued debate. While my bearish colleague focuses on short-term price action and selective metrics, they are missing the forest for the trees. The case for JNJ is not about a speculative, momentum-driven surge; it’s about capital preservation, reliable growth, and compounding income in a volatile market. The recent pullback has made that case s…

End of debate